The pharmaceutical group Sanofi announced Monday evening its indictment for "aggravated deception" and "involuntary injuries" in the case of the marketing of the reference anti-epileptic drug Dépakine, an investigation opened in September 2016.
A high risk of birth defects on the fetus
The molecule in question, sodium valproate, has been marketed since 1967 under the brand name Depakine by Sanofi, but also under generic brands, and is prescribed for people suffering from bipolar disorder, but presents a high risk of congenital malformations on the fetus if it is taken by a pregnant woman.